Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Oncology > ESMO 2018 > Letter from the Editor

Letter from the Editor

Editor
Dr. Stefan Rauh  
Conference
ESMO 2018
    Dear Reader, 

    I am delighted to introduce this year’s Medicom Conference Report of the ESMO Congress, which took place from 19-23 October in Munich. 

    A total of 28,000 attendees from 138 countries is again a record, which is becoming a yearly tradition by now. ESMO members have more than doubled in the last years and have reached over 20,000 by the end of this year’s congress. 

    With 75% of its programme being scientific (rather than educational), it comes as no surprise that the conference was again loaded with important study results; some of which truly practice changing. In consequence, 13 abstracts have been simultaneously published in the highest-ranking medical journals.  

    In this report, you will find hallmark studies involving PIC3K inhibitors, the entry of immunotherapy in triple negative, metastatic breast cancer as well as advanced head and neck cancer,  new potential standards in renal cell cancer, and first-line ovarian cancer (also underlying the importance of identifying subpopulations benefitting from targeting therapy) as well as data consolidating the roleof new combined androgen deprivation therapy and the role of irradiating the primary tumour in advanced prostate cancer.  

    Enjoy reading our peer-reviewed report on the ESMO 2018 Congress! 

    Yours sincerely,  

    Stefan Rauh  



    Posted on